VIVEbiotech highlights in-vivo lentiviral vector expertise at ASGCT 2025
VIVEbiotech showcases its expertise in lentiviral vectors for in-vivo administration at ASGCT 2025, with a talk by Natalia Elizalde and ongoing meetings at booth 1927 in New Orleans.
VIVEbiotech is currently attending the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place this week in vibrant New Orleans. From our booth at the Ernest N. Morial Convention Center, we’re engaging with the global gene and cell therapy community to discuss how our lentiviral vector expertise can support advanced therapies development.
A highlight of the week was the presentation by our Chief Business Development Officer, Natalia Elizalde, during the Tools & Technology Forum. Her talk focused on VIVEbiotech’s proven capabilities in lentiviral vector development and manufacturing—with a particular emphasis on our growing specialization in supplying vectors for in-vivo administration, a field where we are proud to be contributing meaningful advances.
If you’re attending ASGCT2025, don’t miss the chance to meet Natalia and Víctor at booth 1927.